Antiproteinuric effect of oral paricalcitol in chronic kidney disease
- 1 December 2005
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 68 (6), 2823-2828
- https://doi.org/10.1111/j.1523-1755.2005.00755.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol TherapyNew England Journal of Medicine, 2003
- Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremiaKidney International, 2003
- A Retrospective Evaluation of 1,25-Dihydroxyvitamin D3 and Its Potential Effects on Renal Allograft FunctionAmerican Journal of Nephrology, 2002
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in ratsKidney International, 2001
- A Vitamin D Analog Ameliorates Glomerular Injury on Rat GlomerulonephritisThe American Journal of Pathology, 2001
- Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized ratsKidney International, 1998
- Ultraviolet Light May Contribute to Geographic and Racial Blood Pressure DifferencesHypertension, 1997
- 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes.JCI Insight, 1996